• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有 RNF213-、ATIC- 和 TPM3-ALK 融合变异的间变性大细胞淋巴瘤伴间变性淋巴瘤激酶阳性,其特征是重排的 ALK 基因拷贝数增加。

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.

机构信息

Center for Human Genetics, KU Leuven, Belgium.

Center for Cancer Biology, VIB, Leuven, Belgium.

出版信息

Haematologica. 2017 Sep;102(9):1605-1616. doi: 10.3324/haematol.2016.146571. Epub 2017 Jun 28.

DOI:10.3324/haematol.2016.146571
PMID:28659337
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5685221/
Abstract

Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma is characterized by 2p23/ aberrations, including the classic t(2;5)(p23;q35)/ rearrangement present in ~80% of cases and several variant t(2p23/ALK) occurring in the remaining cases. The fusion partners play a key role in the constitutive activation of the chimeric protein and its subcellular localization. Using various molecular technologies, we have characterized ALK fusions in eight recently diagnosed anaplastic large cell lymphoma cases with cytoplasmic-only ALK expression. The identified partner genes included (one case), (one case), (four cases) and (two cases). Notably, all cases showed copy number gain of the rearranged gene, which is never observed in -positive lymphomas. We hypothesized that this could be due to lower expression levels and/or lower oncogenic potential of the variant fusions. Indeed, all partner genes, except , showed lower expression in normal and malignant T cells, in comparison with In addition, we investigated the transformation potential of endogenous Npm1-Alk and Atic-Alk fusions generated by clustered regularly interspaced short palindromic repeats/Cas9 genome editing in Ba/F3 cells. We found that Npm1-Alk has a stronger transformation potential than Atic-Alk, and we observed a subclonal gain of after a longer culture period, which was not observed for Taken together, our data illustrate that lymphomas driven by the variant ATIC-ALK fusion (and likely by RNF213-ALK and TPM3-ALK), but not the classic NPM1-ALK, require an increased dosage of the hybrid gene to compensate for the relatively low and insufficient expression and signaling properties of the chimeric gene.

摘要

间变性大细胞淋巴瘤中存在间变性淋巴瘤激酶(ALK)阳性,其特征是 2p23/异常,包括经典的 t(2;5)(p23;q35)/重排,约 80%的病例存在该重排,其余病例存在几种变体 t(2p23/ALK)。融合伙伴在嵌合蛋白的组成性激活及其亚细胞定位中起着关键作用。使用各种分子技术,我们对 8 例新近诊断的具有仅细胞质 ALK 表达的间变性大细胞淋巴瘤病例中的 ALK 融合进行了特征描述。鉴定的融合伙伴基因包括 CLTC(1 例)、SEPT9(1 例)、TPM3(4 例)和 ATIC(2 例)。值得注意的是,所有病例均显示重排基因的拷贝数增加,而这在 ALK 阳性淋巴瘤中从未观察到。我们假设这可能是由于变体融合的表达水平较低和/或致瘤潜能较低。事实上,除了外,所有伙伴基因在正常和恶性 T 细胞中的表达均低于,此外,我们还研究了通过聚类规则间隔短回文重复序列/Cas9 基因组编辑生成的内源性 Npm1-Alk 和 Atic-Alk 融合在 Ba/F3 细胞中的转化潜能。我们发现 Npm1-Alk 的转化潜能强于 Atic-Alk,并且在较长的培养期后观察到的获得,而对于未观察到。综上所述,我们的数据表明,由变体 ATIC-ALK 融合(可能还有 RNF213-ALK 和 TPM3-ALK)驱动的淋巴瘤,但不是经典的 NPM1-ALK,需要增加 杂交基因的剂量,以补偿嵌合基因相对较低和不足的表达和信号特性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ec8/5685221/587a38e90f6d/1021605.fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ec8/5685221/105f717e6b62/1021605.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ec8/5685221/32d0c18d7a8e/1021605.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ec8/5685221/40a0440b8e5d/1021605.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ec8/5685221/587a38e90f6d/1021605.fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ec8/5685221/105f717e6b62/1021605.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ec8/5685221/32d0c18d7a8e/1021605.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ec8/5685221/40a0440b8e5d/1021605.fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ec8/5685221/587a38e90f6d/1021605.fig4.jpg

相似文献

1
Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.具有 RNF213-、ATIC- 和 TPM3-ALK 融合变异的间变性大细胞淋巴瘤伴间变性淋巴瘤激酶阳性,其特征是重排的 ALK 基因拷贝数增加。
Haematologica. 2017 Sep;102(9):1605-1616. doi: 10.3324/haematol.2016.146571. Epub 2017 Jun 28.
2
ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).ATIC-ALK:一种在间变性大细胞淋巴瘤中由复发性隐匿性染色体倒位inv(2)(p23q35)导致的新型ALK基因融合变异体。
Am J Pathol. 2000 Mar;156(3):781-9. doi: 10.1016/S0002-9440(10)64945-0.
3
Molecular Screening in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: Anaplastic Lymphoma Kinase Analysis, Next-Generation Sequencing Fusion Gene Detection, and T-Cell Receptor Immunoprofiling.间变性大细胞淋巴瘤中间变性淋巴瘤激酶阳性的分子筛选:间变性淋巴瘤激酶分析、下一代测序融合基因检测和 T 细胞受体免疫组化分析。
Mod Pathol. 2024 Mar;37(3):100428. doi: 10.1016/j.modpat.2024.100428. Epub 2024 Jan 23.
4
Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.间变性大细胞淋巴瘤中的Inv(2)(p23q35)通过与ATIC融合诱导组成性间变性淋巴瘤激酶(ALK)酪氨酸激酶激活,ATIC是一种参与嘌呤核苷酸生物合成的酶。
Blood. 2000 Mar 15;95(6):2144-9.
5
A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation.一种由(1;2)(q25;p23)易位产生的间变性大细胞淋巴瘤中的新融合基因TPM3-ALK 。
Blood. 1999 May 1;93(9):3088-95.
6
Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.在间变性大细胞淋巴瘤和炎性肌纤维母细胞瘤中鉴定间变性淋巴瘤激酶(ALK)的新型融合伴侣。
Genes Chromosomes Cancer. 2002 Aug;34(4):354-62. doi: 10.1002/gcc.10033.
7
Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.TPM3-ALK阳性间变性大细胞淋巴瘤的基因表达谱分析揭示了与NPM-ALK阳性间变性大细胞淋巴瘤重叠和独特的模式。
Leuk Res. 2008 Mar;32(3):383-93. doi: 10.1016/j.leukres.2007.07.012. Epub 2007 Aug 27.
8
The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells.在非肿瘤细胞中可检测到NPM-ALK和ATIC-ALK融合基因。
Am J Pathol. 2001 Jun;158(6):2185-93. doi: 10.1016/S0002-9440(10)64690-1.
9
Variant translocation partners of the anaplastic lymphoma kinase (ALK) gene in two cases of anaplastic large cell lymphoma, identified by inverse cDNA polymerase chain reaction.通过反向cDNA聚合酶链反应鉴定的两例间变性大细胞淋巴瘤中间变性淋巴瘤激酶(ALK)基因的变异易位伙伴。
J Clin Exp Hematop. 2014;54(3):225-35. doi: 10.3960/jslrt.54.225.
10
Variant ALK-fusion positive anaplastic large cell lymphoma (ALCL): A population-based paediatric study of the NHL-BFM study group.变异型间变性大细胞淋巴瘤(ALK 融合阳性):NHL-BFM 研究组的一项基于人群的儿科研究。
Br J Haematol. 2024 May;204(5):1894-1898. doi: 10.1111/bjh.19308. Epub 2024 Jan 26.

引用本文的文献

1
The Expression and Molecular Roles of MAMDC2 in MSS Colorectal Cancer with a High Tumor Stromal Ratio.MAMDC2在肿瘤基质比例高的微卫星稳定型结直肠癌中的表达及分子作用
Biomedicines. 2025 May 17;13(5):1217. doi: 10.3390/biomedicines13051217.
2
Nuclear NPM-ALK Protects Myc from Proteasomal Degradation and Contributes to Its High Expression in Cancer Stem-Like Cells in ALK-Positive Anaplastic Large Cell Lymphoma.核 NPM-ALK 保护 Myc 免于蛋白酶体降解,并有助于 ALK 阳性间变大细胞淋巴瘤中的癌症干细胞样细胞中高表达。
Int J Mol Sci. 2023 Sep 20;24(18):14337. doi: 10.3390/ijms241814337.
3
Genetic Variations are Associated with Ventricular Septal Defect in the Chinese Tibetan Population Through Whole-Exome Sequencing.

本文引用的文献

1
Novel ALK fusion in anaplastic large cell lymphoma involving EEF1G, a subunit of the eukaryotic elongation factor-1 complex.间变性大细胞淋巴瘤中涉及真核延伸因子-1复合物亚基EEF1G的新型ALK融合。
Leukemia. 2017 Mar;31(3):743-747. doi: 10.1038/leu.2016.331. Epub 2016 Nov 14.
2
ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern.间变性淋巴瘤激酶(ALK)阳性大B细胞淋巴瘤:棘皮动物微管相关蛋白样4(EML4)-ALK的鉴定及聚焦于ALK免疫组化染色模式的文献综述
Int J Hematol. 2016 Apr;103(4):399-408. doi: 10.1007/s12185-016-1934-1. Epub 2016 Jan 18.
3
通过全外显子组测序发现基因变异与中国藏族人群室间隔缺损相关。
Pharmgenomics Pers Med. 2023 Apr 27;16:389-400. doi: 10.2147/PGPM.S404438. eCollection 2023.
4
Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma.ALK阳性间变性大细胞淋巴瘤中ALK酪氨酸激酶抑制剂耐药的整体观点。
Front Oncol. 2022 Feb 8;12:815654. doi: 10.3389/fonc.2022.815654. eCollection 2022.
5
Impact of Variants in the and Genes on Therapeutic Failure with Imatinib in Patients with Chronic Myeloid Leukemia.基因和 基因变异对慢性髓性白血病患者伊马替尼治疗失败的影响。
Genes (Basel). 2022 Feb 10;13(2):330. doi: 10.3390/genes13020330.
6
Identification of Key Genes Related to CD8+ T-Cell Infiltration as Prognostic Biomarkers for Lung Adenocarcinoma.鉴定与CD8 + T细胞浸润相关的关键基因作为肺腺癌的预后生物标志物
Front Oncol. 2021 Sep 28;11:693353. doi: 10.3389/fonc.2021.693353. eCollection 2021.
7
Identification of Key Genes in Purine Metabolism as Prognostic Biomarker for Hepatocellular Carcinoma.嘌呤代谢关键基因作为肝细胞癌预后生物标志物的鉴定
Front Oncol. 2021 Jan 14;10:583053. doi: 10.3389/fonc.2020.583053. eCollection 2020.
8
Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells.NPM1-ALK 驱动的间变大细胞淋巴瘤细胞的吉瑞替尼的临床前评估。
Mol Cancer Res. 2021 May;19(5):913-920. doi: 10.1158/1541-7786.MCR-20-0738. Epub 2021 Jan 29.
9
Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation.复发弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤或里氏转化患者对依鲁替尼加纳武单抗反应的生物标志物。
Transl Oncol. 2021 Jan;14(1):100977. doi: 10.1016/j.tranon.2020.100977. Epub 2020 Dec 6.
10
Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.T 细胞淋巴瘤、霍奇金淋巴瘤和组织细胞/树突状细胞肿瘤分类的更新。
Expert Rev Hematol. 2019 Oct;12(10):833-843. doi: 10.1080/17474086.2019.1647777. Epub 2019 Jul 31.
The next-generation ALK inhibitors.
下一代ALK抑制剂。
Curr Opin Oncol. 2015 Mar;27(2):118-24. doi: 10.1097/CCO.0000000000000165.
4
Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.系统性间变性大细胞淋巴瘤发病机制的研究进展
Br J Haematol. 2015 Mar;168(6):771-83. doi: 10.1111/bjh.13265. Epub 2015 Jan 6.
5
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.一种具有TRAF1-ALK间变性大细胞淋巴瘤易位的新型患者来源肿瘤移植模型。
Leukemia. 2015 Jun;29(6):1390-401. doi: 10.1038/leu.2014.347. Epub 2014 Dec 23.
6
Variant translocation partners of the anaplastic lymphoma kinase (ALK) gene in two cases of anaplastic large cell lymphoma, identified by inverse cDNA polymerase chain reaction.通过反向cDNA聚合酶链反应鉴定的两例间变性大细胞淋巴瘤中间变性淋巴瘤激酶(ALK)基因的变异易位伙伴。
J Clin Exp Hematop. 2014;54(3):225-35. doi: 10.3960/jslrt.54.225.
7
Aggressive transformation of anaplastic large cell lymphoma with increased number of ALK-translocated chromosomes.间变性大细胞淋巴瘤伴ALK易位染色体数量增加的侵袭性转化
Int J Hematol. 2015 Feb;101(2):198-202. doi: 10.1007/s12185-014-1701-0. Epub 2014 Nov 22.
8
Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-cell lymphoma.整合基因组和转录组分析确定了与肝脾T细胞淋巴瘤发病机制相关的候选基因。
PLoS One. 2014 Jul 24;9(7):e102977. doi: 10.1371/journal.pone.0102977. eCollection 2014.
9
Purification and characterisation of recombinant human eukaryotic elongation factor 1 gamma.重组人真核延伸因子1γ的纯化与鉴定
Protein Expr Purif. 2014 Jul;99:70-7. doi: 10.1016/j.pep.2014.04.003. Epub 2014 Apr 13.
10
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.克唑替尼治疗晚期、化疗耐药的间变性淋巴瘤激酶阳性淋巴瘤患者。
J Natl Cancer Inst. 2014 Feb;106(2):djt378. doi: 10.1093/jnci/djt378.